Project Grant R43DK142279
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$360K
Similar Awards
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $929,940 to Amidebio, LLC to develop novel dual agonist insulin therapies for treating diabetic patients with impaired awareness of hypoglycemia (IAH). The 2-year project aims to pursue manufacturing, formulation, efficacy validation, and safety studies on 3 lead drug candidates to identify a...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...
The federal Project Grant award R21DK138178 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Georgia State University Research Foundation Inc. The $418,560 award supports research to evaluate the therapeutic potential of a new orally active small molecule in obesity-linked diabetic models. Key objectives include analyzing the pharmacokinetic profiles of the new molecule,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a novel Diabetes Targeted Dual Neuromodulation (TDN) therapy. The $345,650 grant will fund a Phase I feasibility study by Reshape Lifesciences Inc., a small business joint venture, to validate the hypothesis that decreasing the amplitude of the high frequency...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
This $1,145,486 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel peripherally acting CB1 neutral antagonists for the treatment of diabetic kidney disease (DKD). The awardee, Makscientific LLC, a for-profit R&D company, will design and synthesize new analogs of compound AM6588 to improve potency, selectivity, oral...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,998 to support the development of advanced stem cell-derived pancreatic islet cell technologies for type 1 diabetes treatment. The key products and services to be delivered include: Assessing the impact of genetically modifying stem cell-derived islet cells to be more resilient to...
This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $500,928 to Pupil Bio, Inc. to develop an early detection test for Type 1 Diabetes (T1D) using next-generation sequencing (NGS) analysis of cell-free DNA (cfDNA) methylation patterns specific to pancreatic beta cells. The goal is to create a non-invasive diagnostic tool that can identify the early stages of T1D...